ShangPharma appoints chief biologics officer
This article was originally published in Scrip
Executive Summary
Contract research organization, ShangPharma has named Dr Mitchell Reff chief biologics officer, effective from 13 January 2014. Prior to joining the Shanghai, China-based firm Dr Reff held a number of positions at Biogen Idec during a 21-year career with the firm, including vice-president of discovery oncology. At ShangPharma he will join the ChemPartner's Biologics Division, which offers pharmaceutical and biotechnology companies strategic and technical expertise to discover and manufacture novel biologics.